AXON Neuroscience Email Format

Biotechnology ResearchBratislava, Slovakia51-200 Employees

AXON Neuroscience is a clinical-stage biotech company founded in 1999 with a specialized team of researchers focused exclusively on tau immunotherapies and tau diagnostic platforms. AXON has identified and wholly owns several compounds which are being investigated as potentially disease-modifying therapies for the treatment of Alzheimer's disease and other tauopathies. The two lead compounds are the active vaccine AADvac1 and the monoclonal antibody AADvac2. The tau vaccine AADvac1 has potential to be the first breakthrough therapy to address Alzheimer's disease and help millions of people suffering from the devastating disease. Axon is also developing a suite of diagnostic assays to more accurately identify patients with potential tau-derived brain diseases that can benefit from its novel therapeutic candidates. 

✕

Access Insights for AXON Neuroscience and Millions of Other Companies

Sign up for full access to AXON Neuroscience information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory